Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
Buy Rating on Coherus Biosciences: Balancing Divestiture with Promising Pipeline and Financial Growth
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations
Coherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Rating
Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)
Why Coherus Biosciences Stock Tumbled on Thursday
Q4 2023 Coherus BioSciences Inc Earnings Call
Buy Rating Affirmed for Coherus Biosciences on Strong Sales and Strategic Restructuring
Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Options Volatility and Implied Earnings Moves Today, March 13, 2024
In the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actions
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.